Target intelligence / Profile preview

Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1)

Target
TRAIL-R1
Molecular classification
Receptor, Membrane receptor, Death receptor, Tumor necrosis factor (TNF) receptor superfamily
01

Overview

Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1/DR4) is a type I transmembrane protein that functions as one of the primary receptors for TNF-related apoptosis-inducing ligand (TRAIL). Upon binding trimeric TRAIL ligand, it induces apoptosis via recruitment of FADD adaptor protein and subsequent activation of caspase cascades. It is mainly expressed on damaged, infected, or malignant cells. As an inducer of programmed cell death specifically in cancerous cells while sparing most normal tissues, it has attracted significant interest as an anticancer therapeutic target. However, clinical translation has been hampered by resistance mechanisms within tumors and insufficient efficacy with current agents. The gene encoding this protein is TNFRSF10A; it shares structural features with other members of the TNF-receptor family but uniquely triggers potent apoptotic signaling upon ligand engagement.

Other names
TRAIL receptor-1Death receptor 4DR4TNFRSF10A
02

Mechanism of action

Drugs or ligands targeting this molecule typically act by binding to TRAIL-R1, inducing its trimerization and recruitment of adaptor proteins such as FADD. This leads to the formation of the death-inducing signaling complex (DISC), activation of caspase 8/10, and initiation of the extrinsic apoptotic pathway

03

Biological functions

Apoptosis induction (cell death)Signal transductionImmune response modulation
04

Disease associations

Cancer (notably in tumor cell apoptosis and as a therapeutic target)Infection (expressed in infected cells)
05

Safety considerations

Potential resistance mechanisms within tumorsOff-target effects leading to unwanted cell death in normal tissuesLimited efficacy observed so far with recombinant TRAIL or agonists in clinical settingsConcerns about immune-related adverse events due to its role in immune modulation
06

Interacting drugs

Luminescent iridium complex-peptide hybrids (experimental)

3 more in the full profile.

07

Biomarkers

TRAIL-R1 expression on tumor cells (for sensitivity to apoptosis-inducing therapies and patient selection)

Beyond the preview

Go deeper on Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call